EVIDENCE BRIEF · CLAIM, SOURCE, LIMIT
A medical claim needs more than a confident tone
MYTH.A polished explanation is evidence by itself.
FACT.Evidence has a traceable source, a defined group of people and a limit. The limit is part of the answer.
Use the label for approved uses and warnings
As of September 2026, Ozempic and Wegovy shared the ingredient semaglutide but had different approved uses.
The current FDA label is the first stop for approved uses, warnings, who was studied and what the medicine is not meant to do.
Use trials for measured outcomes
In a study called STEP 1, adults without diabetes who got semaglutide plus diet and exercise support lost an average of 14.9% of their body weight over 68 weeks. People given a placebo, a dummy shot with no medicine in it, plus the same support lost 2.4%.
That is a group average from a controlled study. It is not a forecast for one person, and the support given inside the trial matters.
Use public records for licences and enforcement
State boards hold licence records. The FDA publishes drug labels, approval records, its list of registered outsourcing facilities (the larger plants that mix medicines in batches) and its warning letters.
A warning letter records an agency allegation at a point in time, not a final court finding.
As of September 2026, a facility list records registration, not approval.
ANNOTATED READING LIST
Evidence, with a note on why it belongs
- Wegovy prescribing information at DailyMed.Use the label to see what the medicine is approved to treat, its warnings and the result tables from its studies.
- The main semaglutide weight trial.Use the published report to see how the study was run, who took part and what it found.
- Official enforcement-letter search.Each letter is an FDA accusation made on a certain date, not a court ruling.